Literature DB >> 11758682

Renal disease in Fabry patients.

J P Grünfeld1, O Lidove, D Joly, F Barbey.   

Abstract

Renal dysfunction is a major complication in hemizygous males with Fabry disease. This often results in end-stage renal failure (ESRF), requiring dialysis or transplantation, on average 10 years after the start of renal impairment. ESRF usually occurs between 40 and 50 years of age, but may occur much earlier. Although progression of renal disease can be rapid, it is variable and may depend on whether there is residual alpha-galactosidase enzyme activity and on environmental or genetic factors. Significant renal disease is much less common in women carriers of the disease. However, renal changes do occur, which may progress to ESRF as in male patients.

Entities:  

Mesh:

Year:  2001        PMID: 11758682     DOI: 10.1023/a:1012475908718

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

Review 1.  Fabry disease: clinical features and recent advances in enzyme replacement therapy.

Authors:  R J Desnick; M P Wasserstein
Journal:  Adv Nephrol Necker Hosp       Date:  2001

2.  Report on management of renal failure in Europe, XXVI, 1995. A conceptual and practical framework for interactive use of the ERA-EDTA Registry.

Authors:  G Tognoni
Journal:  Nephrol Dial Transplant       Date:  1996       Impact factor: 5.992

3.  Coexistence of Fabry's disease and necrotizing and crescentic glomerulonephritis.

Authors:  H K Singh; V Nickeleit; J Kriegsmann; A A Harris; J C Jennette; M J Mihatsch
Journal:  Clin Nephrol       Date:  2001-01       Impact factor: 0.975

4.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

Authors:  M C Gubler; G Lenoir; J P Grünfeld; A Ulmann; D Droz; R Habib
Journal:  Kidney Int       Date:  1978-03       Impact factor: 10.612

5.  Angiokeratoma corporis diffusum--Fabry's disease.

Authors:  A Colombi; A Kostyal; R Bracher; F Gloor; R Mazzi; H Thölen
Journal:  Helv Med Acta       Date:  1967-12

Review 6.  Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease.

Authors:  R E Hillsley; E Hernandez; C Steenbergen; T M Bashore; J K Harrison
Journal:  Am Heart J       Date:  1995-01       Impact factor: 4.749

7.  Ten-year experience in renal transplantation for Fabry's disease.

Authors:  S E Maizel; R L Simmons; C Kjellstrand; D S Fryd
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

8.  Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.

Authors:  D Tsakiris; H K Simpson; E H Jones; J D Briggs; C G Elinder; S Mendel; G Piccoli; J P dos Santos; G Tognoni; Y Vanrenterghem; F Valderrabano
Journal:  Nephrol Dial Transplant       Date:  1996       Impact factor: 5.992

9.  Angiokeratoma corporis diffusum (Fabry's disease) with unusual features in a female patient. Light- and electron-microscopic investigation.

Authors:  A Voglino; M Paradisi; G Dompé; A Onetti Muda; T Faraggiana
Journal:  Am J Dermatopathol       Date:  1988-08       Impact factor: 1.533

10.  Involvement of renal allograft by Fabry's disease.

Authors:  S Popli; Z V Molnar; D J Leehey; J T Daugirdas; D A Roth; M B Adams; J C Cheng; T S Ing
Journal:  Am J Nephrol       Date:  1987       Impact factor: 3.754

View more
  7 in total

Review 1.  Fabry disease-what cardiologists can learn from the nephrologist: a narrative review.

Authors:  Christine E Kurschat
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).

Authors:  Osamu Saito; Eiji Kusano; Tetsu Akimoto; Yasushi Asano; Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Takashi Akiba; Akira Saito; Eiji Ishimura; Motoshi Hattori; Akira Hishida; Chu Guili; Hiroki Maruyama; Masahisa Kobayashi; Touya Ohashi; Ichiro Matsuda; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2015-07-22       Impact factor: 2.801

3.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

4.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

Review 5.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 6.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

7.  Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.

Authors:  Haran Yogasundaram; Anish Nikhanj; Brendan N Putko; Michel Boutin; Shailly Jain-Ghai; Aneal Khan; Christiane Auray-Blais; Michael L West; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.